Biotech technical outlook still bearish

The downtrend in the biotech sector that began on February 26 ain't done yet. On a technical basis, (IBB +0.1%) has been trying to hold on to its wobbly base since its snap back move on April 15. Volume has dried up as the index struggles to stay above the key support level of the 200-day MA. This is not encouraging action for longs.

The relative strength line has dropped from a best-possible rating of 99 down to 68 with no upturn in sight.

Biotech investors should keep their powder dry until the money flow turns decidedly positive. Based on the chart, there is no indication that this is happening yet.


From other sites
Comments (2)
  • DWD Investing
    , contributor
    Comments (13056) | Send Message
    Good idea to keep a eye on that 200 for sure. It would be a good correction if it keeps support at 200. Otherwise, bad news.
    9 May 2014, 12:16 PM Reply Like
  • asp924
    , contributor
    Comments (13) | Send Message
    The 200MA was taken out today. Next stop 290?
    21 Sep 2015, 09:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs